Alice Santos-Silva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3623920/publications.pdf

Version: 2024-02-01

212 papers 5,488 citations

93792 39 h-index 62 g-index

222 all docs 222 docs citations

times ranked

222

8431 citing authors

#	Article	IF	CITATIONS
1	The Signaling Pathway of TNF Receptors: Linking Animal Models of Renal Disease to Human CKD. International Journal of Molecular Sciences, 2022, 23, 3284.	1.8	16
2	Cellular and Molecular Pathways Underlying the Nephrotoxicity of Gadolinium. Toxicological Sciences, 2022, 186, 134-148.	1.4	1
3	Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline. Inflammation Research, 2022, 71, 591-602.	1.6	7
4	Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1371-1378.	1.4	11
5	Neonatal cholestasis: development of a diagnostic decision algorithm from multivariate predictive models. European Journal of Pediatrics, 2021, 180, 1477-1486.	1.3	2
6	MO1046DOPING POLYSULFONE DIALYSIS MEMBRANES WITH HUMAN NEUTROPHIL ELASTASE INHIBITORS - A PILOT STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
7	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. Biomedicines, 2021, 9, 554.	1.4	2
8	IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch. Advances in Hematology, 2021, 2021, 1-12.	0.6	9
9	Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis. Scientific Reports, 2021, 11, 14768.	1.6	13
10	Caffeic acid phenolipids in the protection of cell membranes from oxidative injuries. Interaction with the membrane phospholipid bilayer. Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183727.	1.4	9
11	New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. International Journal of Molecular Sciences, 2021, 22, 43.	1.8	38
12	Neutrophil gelatinase-associated lipocalin detection using a sensitive electrochemical immunosensing approach. Sensors and Actuators B: Chemical, 2020, 304, 127285.	4.0	16
13	In vitro assessment of polyethylene glycol and polyvinylpyrrolidone as hydrophilic additives on bioseparation by polysulfone membranes. Journal of Materials Science, 2020, 55, 1292-1307.	1.7	10
14	Linkage of typically cytosolic peroxidases to erythrocyte membrane – A possible mechanism of protection in Hereditary Spherocytosis. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183172.	1.4	11
15	Protective effect of olive oil polyphenol phase II sulfate conjugates on erythrocyte oxidative-induced hemolysis. Food and Function, 2020, 11, 8670-8679.	2.1	7
16	Doping Polysulfone Membrane with Alphaâ€Tocopherol and Alphaâ€Lipoic Acid for Suppressing Oxidative Stress Induced by Hemodialysis Treatment. Macromolecular Bioscience, 2020, 20, 2000046.	2.1	11
17	Neonatal Cholestasis Over Time: Changes in Epidemiology and Outcome in a Cohort of 154 Patients From a Portuguese Tertiary Center. Frontiers in Pediatrics, 2020, 8, 351.	0.9	7
18	The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. Journal of Artificial Organs, 2019, 22, 14-28.	0.4	43

#	Article	IF	Citations
19	SP666MACHINE LEARNING IN PREDICTION OF VULNERABLE OR RESILIENT END-STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
20	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediators of Inflammation, 2019, 2019, 1-12.	1.4	15
21	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. Renal Failure, 2019, 41, 662-672.	0.8	10
22	SP637INFLAMMATION AND CELL-FREE DNA AS BIOMARKERS FOR THE OUTCOME OF END STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
23	A Microfluidic Deformability Assessment of Pathological Red Blood Cells Flowing in a Hyperbolic Converging Microchannel. Micromachines, 2019, 10, 645.	1.4	48
24	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	1.9	15
25	Disposable electrochemical immunosensor for analysis of cystatin C, a CKD biomarker. Talanta, 2019, 201, 211-216.	2.9	27
26	Hepcidin in chronic kidney disease anemia. Vitamins and Hormones, 2019, 110, 243-264.	0.7	14
27	Weight loss achieved by bariatric surgery modifies high-density lipoprotein subfractions and low-density lipoprotein oxidation towards atheroprotection. Clinical Biochemistry, 2019, 63, 46-53.	0.8	15
28	Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9-thioxanthen-9-one (TX5). EXCLI Journal, 2019, 18, 697-722.	0.5	2
29	Influence of the 6-month physical activity programs on renal function in obese boys. Pediatric Research, 2018, 83, 1011-1015.	1.1	3
30	Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T) as a Risk Factor for Arterial Thrombosis in Georgian Patients. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1061-1066.	0.7	11
31	Nutritional, chemical and antioxidant/pro-oxidant profiles of silverskin, a coffee roasting by-product. Food Chemistry, 2018, 267, 28-35.	4.2	94
32	Impact of Weight Loss on Inflammation and Red Blood Cell Biomarkers after Laparoscopic Gastric Banding Surgery. Journal of Investigative Medicine, 2018, 66, 304-308.	0.7	8
33	Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional Dialysis versus Online-Hemodiafiltration. , 2018, , .		0
34	DNA Damage in End-Stage Renal Disease Patients. Assessment by In Vitro Comet Assay and by Cell-Free DNA Quantification. , 2018 , , .		1
35	SP342HEPCIDIN-25 AND TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS ARE INDEPENDENTLY RELATED WITH ERYTHROPOIESIS IN CHRONIC HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i460-i460.	0.4	1
36	SP348ASSOCIATION OF NT-PRO-BNP WITH ANEMIA, INFLAMMATION AND KIDNEY FUNCTION IN PORTUGUESE DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i462-i462.	0.4	0

#	Article	IF	CITATIONS
37	Cardiovascular Risk Factors Are Correlated with Low Cognitive Function among Older Adults Across Europe Based on The SHARE Database. , 2018, 9, 90.		23
38	Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior. Journal of Nanobiotechnology, 2018, 16, 27.	4.2	27
39	Neutrophil Elastase Inhibitors and Chronic Kidney Disease. International Journal of Biological Sciences, 2018, 14, 1343-1360.	2.6	54
40	Physical exercise intervention at school improved hepcidin, inflammation, and iron metabolism in overweight and obese children and adolescents. Pediatric Research, 2017, 82, 781-788.	1.1	13
41	Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model. International Journal of Pharmaceutics, 2017, 523, 515-530.	2.6	17
42	Physical inactivity among older adults across Europe based on the SHARE database. Age and Ageing, 2017, 46, 71-77.	0.7	143
43	The cross-talk between renal function, inflammation and psoriasis vulgaris. British Journal of Dermatology, 2017, 176, 829-831.	1.4	1
44	The HIF System Response to ESA Therapy in CKDâ€Anemia. , 2017, , .		0
45	Frailty in End-Stage Renal Disease Patients under Dialysis and Its Association with Clinical and Biochemical Markers. Journal of Frailty & Samp; Aging, the, 2017, 6, 103-106.	0.8	9
46	Polymorphisms of the ELANE Gene Promoter Region in End-Stage Chronic Kidney Disease Patients. Genes, 2016, 7, 17.	1.0	2
47	Predictors of Difficulty in Medication Intake in Europe: a Cross-country Analysis Based on SHARE. , 2016, 7, 246.		8
48	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. International Journal of Molecular Sciences, 2016, 17, 28.	1.8	11
49	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPCIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. Nephrology Dialysis Transplantation, 2016, 31, i194-i194.	0.4	1
50	MP585PREVALENCE OF DEPRESSIVE SYMPTOMS IN END STAGE KIDNEY DISEASE PATIENTS UNDER DIALYSIS AND ITS ASSOCIATION WITH SOCIODEMOGRAPHIC AND CLINICAL DATA. Nephrology Dialysis Transplantation, 2016, 31, i536-i536.	0.4	0
51	SP049MALE GENDER AND HYPERTENSION ARE INDEPENDENT VARIABLES ASSOCIATED WITH KIDNEY CANCER IN EUROPE: RESULTS FROM THE SHARE STUDY. Nephrology Dialysis Transplantation, 2016, 31, i102-i102.	0.4	0
52	SPO89IMPAIRED RENAL ENDOTHELIAL NITRIC OXIDE SYNTHASE AND RETICULOCYTE PRODUCTION AS MODULATORS OF HYPERTENSION INDUCED BY RECOMBINANT HUMAN ERYTHROPOIETIN IN THE RAT. Nephrology Dialysis Transplantation, 2016, 31, i115-i115.	0.4	0
53	MP600SELF REPORTED END STAGE RENAL DISEASE ADHERENCE QUESTIONNAIRE AND ITS ASSOCIATION WITH POTENTIAL BIOMARKERS OF NON ADHERENCE. Nephrology Dialysis Transplantation, 2016, 31, i541-i541.	0.4	0
54	The triad psoriasis–obesity–adipokine profile. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1876-1885.	1.3	44

#	Article	IF	CITATIONS
55	Different hydroxyapatite magnetic nanoparticles for medical imaging: Its effects on hemostatic, hemolytic activity and cellular cytotoxicity. Colloids and Surfaces B: Biointerfaces, 2016, 146, 363-374.	2.5	59
56	Renal riskâ€benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 343-354.	0.9	10
57	Adipokine Gene Single-Nucleotide Polymorphisms in Portuguese Obese Adolescents: Associations with Plasma Concentrations of Adiponectin, Resistin, IL-6, IL-1β, and TNF-α. Childhood Obesity, 2016, 12, 300-313.	0.8	18
58	Risk factors for mortality in end-stage kidney disease patients under online-hemodiafiltration: three-year follow-up study. Biomarkers, 2016, 21, 544-550.	0.9	3
59	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. Biochimie, 2016, 125, 150-162.	1.3	11
60	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sciences, 2016, 151, 147-156.	2.0	4
61	Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model. International Journal of Pharmaceutics, 2016, 513, 332-346.	2.6	15
62	Impact of a School-Based Intervention Protocol—ACORDA Project—On Adipokines in an Overweight and Obese Pediatric Population. Pediatric Exercise Science, 2016, 28, 407-416.	0.5	19
63	End-stage renal disease adherence questionnaire: translation and validation to the portuguese language. Renal Failure, 2016, 38, 1633-1638.	0.8	14
64	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	0.6	6
65	Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. British Journal of Dermatology, 2016, 174, 414-416.	1.4	12
66	Effects of 6-month soccer and traditional physical activity programmes on body composition, cardiometabolic risk factors, inflammatory, oxidative stress markers and cardiorespiratory fitness in obese boys. Journal of Sports Sciences, 2016, 34, 1822-1829.	1.0	46
67	Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Reviews, 2016, 30, 65-72.	2.8	28
68	Exercise intervention and cardiovascular risk factors in obese children. Comparison between obese youngsters taking part in a physical activity school-based programme with and without individualised diet counselling: the ACORDA project. Annals of Human Biology, 2016, 43, 183-190.	0.4	12
69	Liver iron is a major regulator of hepcidin gene expression via <scp>BMP/SMAD</scp> pathway in a rat model of chronic renal failure under treatment with high r <scp>H</scp> u <scp>EPO</scp> doses. BioFactors, 2016, 42, 296-306.	2.6	8
70	Performance of In Silico Tools for the Evaluation of <i>UGT1A1 </i> Missense Variants. Human Mutation, 2015, 36, 1215-1225.	1.1	21
71	SELFâ€REPORTED MEDICATION ADHERENCE IN PATIENTS WITH END TAGE KIDNEY DISEASE UNDERGOING ONLINEâ€HAEMODIAFILTRATION. Journal of Renal Care, 2015, 41, 231-238.	0.6	8
72	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. PLoS ONE, 2015, 10, e0124048.	1.1	33

#	Article	lF	CITATIONS
73	Aging and Cardiovascular Risk. BioMed Research International, 2015, 2015, 1-2.	0.9	12
74	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. Quality of Life Research, 2015, 24, 1327-1335.	1.5	25
75	Bilirubin is independently associated with oxidized LDL levels in young obese patients. Diabetology and Metabolic Syndrome, 2015, 7, 4.	1.2	15
76	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration., 2015, 6, 17.		6
77	Effects of the olive oil phenol metabolite 3,4-DHPEA-EDAH (sub) 2 (sub) on human erythrocyte oxidative damage. Food and Function, 2015, 6, 2350-2356.	2.1	9
78	Biochemical and Cellular Changes in Leukocyte-Depleted Red Blood Cells Stored for Transfusion. Transfusion Medicine and Hemotherapy, 2015, 42, 46-51.	0.7	22
79	Comparison between CDC and WHO BMI z-score and their relation with metabolic risk markers in Northern Portuguese obese adolescents. Diabetology and Metabolic Syndrome, 2015, 7, 32.	1.2	9
80	Hydroxyapatite-based materials of marine origin: A bioactivity and sintering study. Materials Science and Engineering C, 2015, 51, 309-315.	3.8	53
81	Peroxiredoxin 2, glutathione peroxidase, and catalase in the cytosol and membrane of erythrocytes under H ₂ O ₂ -induced oxidative stress. Free Radical Research, 2015, 49, 990-1003.	1.5	53
82	Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evidence, 2014, 9, 89.	4.7	21
83	Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese. PLoS ONE, 2014, 9, e98467.	1.1	22
84	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. BioMed Research International, 2014, 2014, 1-17.	0.9	9
85	Type of Vascular access and Location in Online Hemodiafiltration and its Association with Patient's Perception of Health-Related Quality of Life. Journal of Vascular Access, 2014, 15, 175-182.	0.5	21
86	Waldenström's macroglobulinemia - a review. Revista Da Associação Médica Brasileira, 2014, 60, 490-499.	0.3	2
87	EXPERIMENTAL PATHOLOGY. Nephrology Dialysis Transplantation, 2014, 29, iii201-iii208.	0.4	0
88	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 2014, 15, 8979-8997.	1.8	26
89	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. BioMed Research International, 2014, 2014, 1-9.	0.9	12
90	Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia. BioMed Research International, 2014, 2014, 1-10.	0.9	5

#	Article	IF	CITATIONS
91	Adiponectin, Leptin, and Chemerin in Elderly Patients with Type 2 Diabetes Mellitus: A Close Linkage with Obesity and Length of the Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	51
92	Modulation of human dermal microvascular endothelial cell and human gingival fibroblast behavior by micropatterned silica coating surfaces for zirconia dental implant applications. Science and Technology of Advanced Materials, 2014, 15, 025001.	2.8	28
93	Circulating cell-free DNA levels in Portuguese patients with psoriasis vulgaris according to severity and therapy. British Journal of Dermatology, 2014, 170, 939-942.	1.4	17
94	Cumulative Mitoxantroneâ€Induced Haematological and Hepatic Adverse Effects in a Subchronic <i>In vivo</i> Study. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 254-262.	1,2	13
95	Adiponectin and markers of metabolic syndrome in obese children and adolescents: impact of 8-mo regular physical exercise program. Pediatric Research, 2014, 76, 159-165.	1.1	26
96	Inflammatory markers of cardiovascular disease risk in <scp>P</scp> ortuguese psoriatic patients: relation with narrowâ€band ultraviolet <scp>B</scp> and psoralen plus ultraviolet <scp>A</scp> . International Journal of Dermatology, 2014, 53, 393-396.	0.5	4
97	Biocompatibility and hemocompatibility of polyvinyl alcohol hydrogel used for vascular grafting-In vitroandin vivostudies. Journal of Biomedical Materials Research - Part A, 2014, 102, n/a-n/a.	2.1	84
98	The effect of olive leaf supplementation on the constituents of blood and oxidative stability of red blood cells. Journal of Functional Foods, 2014, 9, 271-279.	1.6	21
99	Biomarkers of psoriasis severity and therapy monitoring. World Journal of Dermatology, 2014, 3, 15.	0.5	8
100	The Positive Effect of Moderate Walking Exercise on Chemerin Levels in Portuguese Patients With Type 2 Diabetes Mellitus. Journal of Investigative Medicine, 2014, 62, 350-353.	0.7	22
101	CKD ANAEMIA. Nephrology Dialysis Transplantation, 2014, 29, iii140-iii147.	0.4	0
102	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression., 2014, 5, 356-65.		12
103	Letter to the Editor: A potential mechanism for the pathogenesis of psoriasis <i>vulgaris</i> International Journal of Dermatology, 2013, 52, 1429-1432.	0.5	0
104	The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen. Journal of Bioenergetics and Biomembranes, 2013, 45, 383-396.	1.0	4
105	The role of adipocytes in the modulation of iron metabolism in obesity. Obesity Reviews, 2013, 14, 771-779.	3.1	56
106	Factors Associated with the Length of Remission of Psoriasis Vulgaris. Clinical Drug Investigation, 2013, 33, 855-860.	1.1	4
107	The in vitro and in vivo genotoxicity of isotretinoin assessed by cytokinesis blocked micronucleus assay and comet assay. Toxicology in Vitro, 2013, 27, 900-907.	1.1	3
108	Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: Potential mechanisms of hepatotoxicity. Toxicology, 2013, 306, 93-100.	2.0	22

#	Article	IF	Citations
109	Bilirubin Levels and Redox Status in a Young Healthy Population. Acta Haematologica, 2013, 130, 57-60.	0.7	4
110	Principal Determinants of the Length of Remission of Psoriasis Vulgaris After Topical, NB-UVB, and PUVA Therapy. American Journal of Clinical Dermatology, 2013, 14, 49-53.	3.3	17
111	Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen–ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 753, 42-47.	0.9	8
112	Protective Activity of Hydroxytyrosol Metabolites on Erythrocyte Oxidative-Induced Hemolysis. Journal of Agricultural and Food Chemistry, 2013, 61, 6636-6642.	2.4	35
113	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	0.6	45
114	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 2013, 17, n/a-n/a.	0.4	11
115	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 2013, 35, 1392-1398.	0.8	10
116	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. Journal of Vascular Access, 2013, 14, 335-341.	0.5	3
117	Adipokines, Oxidized Low-Density Lipoprotein, and C-Reactive Protein Levels in Lean, Overweight, and Obese Portuguese Patients with Type 2 Diabetes. ISRN Obesity, 2013, 2013, 1-7.	2.2	21
118	Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. Journal of Pharmacy and Bioallied Sciences, 2012, 4, 76.	0.2	18
119	Comparison of Bio-Plex measurements with standard techniques. Clinical Chemistry and Laboratory Medicine, 2012, 50, 399-402.	1.4	1
120	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	0.8	4
121	Inflammatory Disturbances in Preeclampsia: Relationship between Maternal and Umbilical Cord Blood. Journal of Pregnancy, 2012, 2012, 1-10.	1.1	68
122	Main Determinants of PON1 Activity in Hemodialysis Patients. American Journal of Nephrology, 2012, 36, 317-323.	1.4	16
123	Bilirubin Dependence on UGT1A1 Polymorphisms, Hemoglobin, Fasting Time and Body Mass Index. American Journal of the Medical Sciences, 2012, 343, 114-118.	0.4	16
124	Voltammetric immunosensor for the diagnosis of celiac disease based on the quantification of anti-gliadin antibodies. Sensors and Actuators B: Chemical, 2012, 163, 253-259.	4.0	28
125	Study of erythrocyte oxidative stress and senescence markers in Hereditary Spherocytosis patients. Free Radical Biology and Medicine, 2012, 53, S205.	1.3	0
126	Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis . Scandinavian Journal of Urology and Nephrology, 2012, 46, 461-465.	1.4	1

#	Article	IF	Citations
127	Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients. American Journal of Clinical Dermatology, 2012, 13, 37-47.	3.3	15
128	Evaluation of chitoligosaccharides effect upon probiotic bacteria. International Journal of Biological Macromolecules, 2012, 50, 148-152.	3.6	12
129	Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells, Molecules, and Diseases, 2012, 48, 166-172.	0.6	20
130	The roles of cells and cytokines in the pathogenesis of psoriasis. International Journal of Dermatology, 2012, 51, 389-398.	0.5	115
131	Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model. Marine Drugs, 2012, 10, 2661-2675.	2.2	43
132	Oxidized lowâ€density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International, 2012, 16, 481-490.	0.4	21
133	Cardiovascular Risk Factors in Portuguese Obese Children and Adolescents: Impact of Small Reductions in Body Mass Index Imposed by Lifestyle Modifications. The Open Biochemistry Journal, 2012, 6, 43-50.	0.3	19
134	Complementary markers for the clinical severity classification of hereditary spherocytosis in unsplenectomized patients. Blood Cells, Molecules, and Diseases, 2011, 46, 166-170.	0.6	16
135	Cytotoxicity and genotoxicity of chitooligosaccharides upon lymphocytes. International Journal of Biological Macromolecules, 2011, 49, 433-438.	3.6	24
136	Erythropoiesis versus inflammation in Hereditary Spherocytosis clinical outcome. Clinical Biochemistry, 2011, 44, 1137-1143.	0.8	6
137	Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. Journal of Dermatology, 2011, 38, 816-819.	0.6	6
138	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. Hemodialysis International, 2011, 15, 429-431.	0.4	4
139	Apoptosis of Peripheral CD4 ⁺ T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. Renal Failure, 2011, 33, 138-143.	0.8	25
140	Câ€reactive protein and leucocyte activation in psoriasis <i>vulgaris</i> according to severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 789-796.	1.3	107
141	Celiac disease diagnosis and gluten-free food analytical control. Analytical and Bioanalytical Chemistry, 2010, 397, 1743-1753.	1.9	26
142	<i>In vitro</i> studies with †acatalasemicâ€like†erythrocytes and hydrogen peroxide: attention to the formation of lysis resistant erythrocytes. International Journal of Laboratory Hematology, 2010, 32, 127-131.	0.7	2
143	Antioxidant activity of chitooligosaccharides upon two biological systems: Erythrocytes and bacteriophages. Carbohydrate Polymers, 2010, 79, 1101-1106.	5.1	71
144	Circulating adipokine levels in Portuguese patients with psoriasis <i>vulgaris</i> according to body mass index, severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1386-1394.	1.3	104

#	Article	IF	Citations
145	Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodialysis International, 2010, 14, 295-301.	0.4	26
146	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. British Journal of Dermatology, 2010, 163, 1282-1290.	1.4	120
147	Erythrocyte membrane protein destabilization <i>versus</i> clinical outcome in 160 Portuguese Hereditary Spherocytosis patients. British Journal of Haematology, 2010, 149, 785-794.	1.2	25
148	Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Renal Failure, 2010, 32, 1073-1080.	0.8	10
149	Psoriasis Therapy and Cardiovascular Risk Factors. American Journal of Clinical Dermatology, 2010, 11, 423-432.	3.3	36
150	Powerful Protective Role of 3,4-Dihydroxyphenylethanolâ^'Elenolic Acid Dialdehyde against Erythrocyte Oxidative-Induced Hemolysis. Journal of Agricultural and Food Chemistry, 2010, 58, 135-140.	2.4	52
151	Anti-Inflammatory Activity of Chitooligosaccharides in Vivo. Marine Drugs, 2010, 8, 1763-1768.	2.2	109
152	Plant aqueous extracts: Antioxidant capacity via haemolysis and bacteriophage P22 protection. Food Control, 2010, 21, 633-638.	2.8	19
153	Hereditary spherocytosis and the (TA)nTAA polymorphism of UGT1A1 gene promoter region—A comparison of the bilirubin plasmatic levels in the different clinical forms. Blood Cells, Molecules, and Diseases, 2010, 44, 117-119.	0.6	7
154	Leukocyte Count versus C-Reactive Protein Levels in Obese Portuguese Patients Aged 6-12 Years Old. The Open Biochemistry Journal, 2010, 4, 72-76.	0.3	21
155	Effect of Recombinant Human Erythropoietin in a Rat Model of Moderate Chronic Renal Failure - Focus on Inflammation, Oxidative Stress and Function/Renoprotection. The Open Drug Discovery Journal, 2010, 2, 25-32.	0.8	1
156	Lipoprotein(a) Levels in Obese Portuguese Children and Adolescents: Contribution of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene. JAMA Pediatrics, 2009, 163, 393.	3.6	2
157	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	0.7	41
158	Lipid Profile in Portuguese Obese Children and Adolescents. JAMA Pediatrics, 2009, 163, 1030-6.	3.6	11
159	Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors, 2009, 27, 345-351.	0.5	31
160	Characterization of a Rat Model of Moderate Chronic Renal Failure—Focus on Hematological, Biochemical, and Cardio-Renal Profiles. Renal Failure, 2009, 31, 833-842.	0.8	8
161	Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition, 2009, 25, 330-339.	1.1	91
162	Effects of olive oil polyphenols on erythrocyte oxidative damage. Molecular Nutrition and Food Research, 2009, 53, 609-616.	1.5	95

#	Article	IF	CITATIONS
163	Erythropoietin Promotes Deleterious Cardiovascular Effects and Mortality Risk in a Rat Model of Chronic Sports Doping. Cardiovascular Toxicology, 2009, 9, 201-210.	1.1	22
164	Linkage of cytosolic peroxiredoxin 2 to erythrocyte membrane imposed by hydrogen peroxide-induced oxidative stress. Blood Cells, Molecules, and Diseases, 2009, 43, 68-73.	0.6	31
165	Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine. Transplantation Proceedings, 2009, 41, 868-873.	0.3	37
166	Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. Journal of Dermatological Science, 2009, 55, 202-204.	1.0	53
167	Erythrocyte changes in preeclampsia: relationship between maternal and cord blood erythrocyte damage. Journal of Perinatal Medicine, 2009, 37, 19-27.	0.6	16
168	Inflammation, T-Cell Phenotype, and Inflammatory Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy. Journal of Clinical Immunology, 2008, 28, 268-275.	2.0	77
169	Voltammetric and DFT Studies on Viloxazine: Analytical Application to Pharmaceuticals and Biological Fluids. Electroanalysis, 2008, 20, 1454-1462.	1.5	11
170	Fetal lipoprotein changes in preâ€eclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 628-634.	1.3	35
171	Effects of Chitooligosaccharides on Human Red Blood Cell Morphology and Membrane Protein Structure. Biomacromolecules, 2008, 9, 3346-3352.	2.6	51
172	Changes in Red Blood Cells Membrane Protein Composition during Hemodialysis Procedure. Renal Failure, 2008, 30, 971-975.	0.8	16
173	Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies. Thrombosis Research, 2008, 123, 219-224.	0.8	20
174	IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 2008, 41, 134-135.	0.6	4
175	Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis. Blood Cells, Molecules, and Diseases, 2008, 41, 5-9.	0.6	38
176	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	1.4	36
177	Neutrophil Activation and Resistance to Recombinant Human Erythropoietin Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 935-940.	1.4	42
178	Altered Erythrocyte Membrane Protein Composition in Chronic Kidney Disease Stage 5 Patients under Haemodialysis and Recombinant Human Erythropoietin Therapy. Blood Purification, 2008, 26, 267-273.	0.9	18
179	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	0.7	4
180	Similarities Between Pre-Eclampsia and Atherosclerosis: A Protective Effect of Physical Exercise?. Current Medicinal Chemistry, 2008, 15, 2223-2229.	1,2	17

#	Article	IF	CITATIONS
181	Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. The Open Clinical Chemistry Journal, 2008, 1, 57-63.	0.7	11
182	Dual Effect of Nitrate Therapy for Cyclosporine-Induced Hypertension on Vascular and Platelet Morphofunctional Markers; An Animal Model. Transplantation Proceedings, 2007, 39, 2501-2506.	0.3	5
183	Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy. Transplantation Proceedings, 2007, 39, 2494-2500.	0.3	15
184	PO9-243 EXERCISE TRAINING AND THE INFLAMMATORY RESPONSE IN ZDF (TYPE 2) DIABETIC RATS. Atherosclerosis Supplements, 2007, 8, 77.	1.2	0
185	Squareâ€Wave Adsorptiveâ€Stripping Voltammetric Detection in the Quality Control of Fluoxetine. Analytical Letters, 2007, 40, 1131-1146.	1.0	25
186	Green tea consumption improves plasma lipid profiles in adults. Nutrition Research, 2006, 26, 604-607.	1.3	21
187	The effect of green tea in oxidative stress. Clinical Nutrition, 2006, 25, 790-796.	2.3	92
188	Pre-eclampsia Versus Cardiovascular Disease Versus CRP. Current Hypertension Reviews, 2006, 2, 317-323.	0.5	0
189	Erythropoietin levels in the different clinical forms of hereditary spherocytosis. British Journal of Haematology, 2005, 131, 534-542.	1.2	17
190	Protein deficiency balance as a predictor of clinical outcome in hereditary spherocytosis. European Journal of Haematology, 2005, 74, 374-380.	1.1	24
191	Electroanalytical study of fluvoxamine. Analytical and Bioanalytical Chemistry, 2005, 382, 1662-1668.	1.9	21
192	High-density lipoprotein particles may regulate hemostasis in human pregnancy. Fertility and Sterility, 2005, 84, 1021-1022.	0.5	2
193	Oxidized-LDL levels in normal and pre-eclamptic pregnancies: Contribution of LDL particle size. Atherosclerosis, 2005, 183, 185-186.	0.4	8
194	Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 123, 46-51.	0.5	124
195	Erythrocyte damage in mild and severe psoriasis. British Journal of Dermatology, 2004, 150, 232-244.	1.4	61
196	The inflammatory response in mild and in severe psoriasis. British Journal of Dermatology, 2004, 150, 917-928.	1.4	221
197	Coexistence of congenital red cell pyruvate kinase and band 3 deficiency. International Journal of Laboratory Hematology, 2004, 26, 297-300.	0.2	5
198	LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis, 2004, 177, 391-399.	0.4	82

#	Article	IF	CITATIONS
199	Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 112, 9-15.	0.5	40
200	Neutrophil Activation and Câ€Reactive Protein Concentration in Preeclampsia. Hypertension in Pregnancy, 2003, 22, 129-141.	0.5	62
201	Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis, 2002, 162, 425-432.	0.4	148
202	Lipoprotein(a): a longitudinal versus a cross-sectional study in normal pregnancy and its levels in preeclampsia. Atherosclerosis, 2002, 165, 393-395.	0.4	11
203	Erythrocyte damage and leukocyte activation in ischemic stroke. Clinica Chimica Acta, 2002, 320, 29-35.	0.5	43
204	Band 3 as a marker of erythrocyte changes in pregnancy. European Journal of Haematology, 2002, 69, 145-151.	1.1	23
205	Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 1250-1255.	1.1	46
206	Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta, 2001, 303, 33-39.	0.5	182
207	Leukocyte activation, erythrocyte damage, lipid profile and oxidative stress imposed by high competition physical exercise in adolescents. Clinica Chimica Acta, 2001, 306, 119-126.	0.5	100
208	Hematological and Biochemical Parameters in Hereditary Spherocytosis Under Oxidative Stress. , 1999, , 337-345.		0
209	Erythrocyte membrane band 3 profile imposed by cellular aging, by activated neutrophils and by neutrophilic elastase. Clinica Chimica Acta, 1998, 275, 185-196.	0.5	27
210	Altered erythrocyte membrane band 3 profile as a marker in patients at risk for cardiovascular disease. Atherosclerosis, 1995, 116, 199-209.	0.4	32
211	Adiponectin, Inflammation and Cardiometabolic Risk Factors in Paediatric Obese Patients: Impact of Interventional Studies. , 0, , .		1
212	Adipokines, C-Reactive Protein and Lipid Profile Levels in Hypertensive Type 2 Diabetic Portuguese Patients. Research in Endocrinology, 0 , 1 -9.	0.0	1